Compassionate use program for dupilumab
Treatments studied
Part of Blood & lymphatic, Digestive system, Eyes & vision, Genetic & congenital, Immune system & allergy, Skin clinical trials.
This program provides access to an experimental medication called dupilumab for people with serious conditions when no other treatments have worked. It is not a regular clinical trial, but a special access program for patients who have no other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a serious or life-threatening condition that has not gotten better with approved treatments.
- You need to have no other treatment options left to try.
- Your doctor must be willing to support your application and work with the program.
- You must be able to commit to regular medical visits and monitoring during the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides continued access to dupilumab, an injectable medication that may help reduce severe allergic reactions to food, for adults who previously completed a related study. It is designed for those who tolerated the treatment well and need ongoing therapy.
This is a registry—an observational study tracking patients with COPD (chronic lung disease) who are newly starting a medication called dupilumab. Researchers will follow your health outcomes to learn how well this treatment works in real-world practice.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This study looks at how well and how safely the medicine Dupilumab works for children whose asthma is not well-controlled with their current inhalers. The goal is to see if it can help reduce asthma attacks and improve daily life.
This trial tests if dupilumab can help people with hard-to-treat stomach ulcers linked to eosinophilic gastrointestinal disorders (EGIDs), where a type of white blood cell builds up in the gut. It may offer a new option for those who haven't gotten better with other treatments.
This study looks at how well dupilumab works for people with uncontrolled COPD who have high levels of a certain white blood cell (eosinophils). It collects information from routine doctor visits to see how patients feel and if the treatment is safe.
Hear when a new Type 2 Inflammatory Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.